Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials

Genitourinary Cancer

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Ann Oncol

Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, Porta C, Suárez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Scheffold C, Askelson M, Panzica J, Zhang J, van Kooten Losio M, Choueiri TK

doi: 10.1016/j.annonc.2025.09.006

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Ann Oncol

Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ

doi: 10.1016/j.annonc.2026.02.017

Gastrointestinal Cancer

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma

Ann Oncol

Chen YX, Jin Y, Chen YK, Cui C, Yao J, Zhang Y, Li M, Cao G, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Luo X, Zhang X, Xie H, Zou J, Xu RH, Wang ZX, Wang F, JUPITER-06 investigators

doi: 10.1016/j.annonc.2026.01.005

Lung, Respiratory and Thoracic Cancer

Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences

Lung Cancer

Lamberti G, Andrini E, Zappi A, Di Odoardo A, Formelli MG, Campana D

doi: 10.1016/j.lungcan.2026.109376

Gastrointestinal Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

JAMA Oncol

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

doi: 10.1001/jamaoncol.2025.5144

Lung, Respiratory and Thoracic Cancer

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Clin Cancer Res

Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung YH, Ip V, Li G, Graf RP, Ready N

doi: 10.1158/1078-0432.CCR-25-0952

Head and Neck Cancer

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Exp Hematol Oncol

Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N

doi: 10.1186/s40164-025-00703-x

RECOMMENDED

Breast Cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY

doi: 10.1016/S1470-2045(25)00545-5

Genitourinary Cancer

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

Ann Oncol

Motzer RJ, Albiges L, Aguirre SAT, Kanesvaran R, Centkowski P, Reimers MA, Sade JP, Pouessel D, Biscaldi E, Esteban E, Arranz Arija JÁ, Tykodi SS, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun DA, Powles T, Choueiri TK

doi: 10.1016/j.annonc.2026.02.011

Related content

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma

Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study